Literature DB >> 18490123

Encephalopathy with a reversible splenial lesion is associated with hyponatremia.

Jun-ichi Takanashi1, Hiroko Tada, Masayuki Maeda, Motomasa Suzuki, Hitoshi Terada, A James Barkovich.   

Abstract

We have encountered several patients with clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) associated hyponatremia. In order to better understand this phenomenon, Na levels were evaluated in a series of patients with MERS. Na was 131.8+/-4.1 mmol/l (mean+/-SD, range 121-140) in 30 patients with MERS; 138.3+/-2.7 mmol/l (range 134-144) in age-matched 21 patients with upper respiratory infection; 136.6+/-2.5 mmol/l (range 132-140) in nine patients with other type of encephalopathy; and 136.2+/-2.6 mmol/l (range 132-140) in 17 patients with febrile seizures. Twenty-five of the thirty patients with MERS had Na<136 mmol/l. There were significant differences between the Na levels of patients with MERS and those with other groups. It is not possible, from the clinical perspective, to completely separate MERS from hyponatremic encephalopathy or to rule out hyponatremia as a contributing factor of MERS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490123     DOI: 10.1016/j.braindev.2008.04.002

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  33 in total

1.  Rotavirus-infected children with clinically mild encephalopathy with a reversible splenial lesion (MERS).

Authors:  Tadafumi Yokoyama; Shimpei Yamada; Nobuyuki Doichi; Eiji Kato
Journal:  BMJ Case Rep       Date:  2013-07-16

2.  Leukoencephalopathic changes on magnetic resonance imaging associated with a thermogenic dietary supplement (Thermatrim).

Authors:  Cristina I Olivas-Chacon; Manuel Treviño-Garcia; John James Chua-Tuan; Jose M Rodriguez-Cordero; Alfonso H Gil-Valadez; Nassim Akle; Jesus E Calleros; Luis R Ramos-Duran
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-07

Review 3.  Mild encephalitis/encephalopathy with a reversible splenial lesion: five cases and a literature review.

Authors:  Jing Jing Pan; You-Yan Zhao; Chao Lu; Yu-Hua Hu; Yang Yang
Journal:  Neurol Sci       Date:  2015-07-01       Impact factor: 3.307

4.  Sudden worsening after subdural haematoma surgery: will there be a corpus callosum injury?

Authors:  Pier Paolo Panciani; Elena Roca; Giovanni Lodoli; Marco Maria Fontanella
Journal:  BMJ Case Rep       Date:  2014-05-26

5.  Kawasaki disease complicated with reversible splenial lesion and acute myocarditis.

Authors:  Shinji Itamura; Masahiro Kamada; Naomi Nakagawa
Journal:  Pediatr Cardiol       Date:  2011-03-06       Impact factor: 1.655

6.  Reversible splenial lesion on the corpus callosum in nonfulminant hepatitis A presenting as encephalopathy.

Authors:  Soon Young Ko; Byung Kook Kim; Dong Wook Kim; Jeong Han Kim; Won Hyeok Choe; Hee Yeon Seo; So Young Kwon
Journal:  Clin Mol Hepatol       Date:  2014-12-24

7.  A Neonatal Case of Mild Encephalopathy/Encephalitis with a Reversible Splenial Lesion.

Authors:  Yuzuki Oki; Tomohide Yoshida; Akira Yogi; Shingo Kurokawa; Hideki Goya; Mayumi Tsukayama; Sadao Nakamura; Keiko Mekaru; Koichi Nakanishi
Journal:  Child Neurol Open       Date:  2022-08-01

Review 8.  [Kawasaki disease complicated with mild encephalitis/encephalopathy with a reversible splenial lesion: A case report and literature review].

Authors:  Y Y DU; J Wang; L He; L N Ji; X W Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

9.  Mild encephalitis/encephalopathy with a reversible splenial lesion in children.

Authors:  Adalet Elçin Yıldız; Hülya Maraş Genç; Esra Gürkaş; Havva Akmaz Ünlü; İbrahim Halil Öncel; Alev Güven
Journal:  Diagn Interv Radiol       Date:  2018 Mar-Apr       Impact factor: 2.630

10.  Mild encephalitis/encephalopathy with a reversible splenial lesion associated with respiratory syncytial virus infection in infants.

Authors:  Xue-Lin Li; Jinming Han; Zhong-Rui Yan; Bing-Wei Zhang; Hai-Yang Wang
Journal:  J Neurovirol       Date:  2021-07-05       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.